Is remission of depressive symptoms in primary care a realistic goal? A meta-analysis

BMC Family Practice

Volumn 5, Issue , 2004, Pages

  Dawson, Marliese Y ^a   Michalak, Erin E ^a   Waraich, Paul ^a   Anderson, J Ellen ^b   Lam, Raymond W ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b Universityof British Columbia ^*  (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CITALOPRAM; ESCITALOPRAM; FLUOXETINE; MIRTAZAPINE; NORTRIPTYLINE; PAROXETINE; PLACEBO; SERTRALINE;

ADULT; AGED; ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; COMPUTER PROGRAM; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HEALTH CARE; HUMAN; MAJOR DEPRESSION; MALE; META ANALYSIS; PATIENT CARE; PATIENT COUNSELING; PRIMARY MEDICAL CARE; PSYCHIATRIC TREATMENT; PSYCHOTHERAPY; RANDOMIZED CONTROLLED TRIAL; REMISSION; DEPRESSIVE DISORDER, MAJOR; MENTAL HEALTH SERVICE; PRIMARY HEALTH CARE; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, MAJOR; HUMANS; MENTAL HEALTH SERVICES; PRIMARY HEALTH CARE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REMISSION INDUCTION;

EID: 5444254414     PISSN: 14712296     EISSN: None     Source Type: Journal    
DOI: 10.1186/1471-2296-5-19     Document Type: Article

References (43)

1. Parikh SV, Lam RW: Clinical guidelines for the treatment of depressive disorders, I. Definitions, prevalence, and health burden. Can J Psychiatry 2001, 46 Suppl 1:13S-20S.
2. Statistics Canada : Canadian Community Health Survey: Mental health and well-being. www statcan ca/Daily/English/030903/ d030903a htm, accessed November 9, 2003.
3. Desjardins B, Laurier C: The burden of depression in Canada. Value in Health 2002, 5:229.
4. Murray CJ, Lopez AD: Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 1997, 349:1498-1504.
5. Hamilton M: Development of a rating scale for primary depressive illness. Br J Soc Clin Psych 1967, 6:278-296.
6. Montgomery SA, Asberg M: A new depression scale designed to be sensitive to change. Br J Psychiatry 1979, 134:382-389.
7. Frank E, Prien RF, Jarrett RB, Keller MB, Kupfer DJ, Lavori PW, Rush AJ, Weissman MM: Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence. Arch Gen Psychiatry 1991, 48:851-855.
8. Judd LL, Akiskal HS, Maser JD, Zeller PJ, Endicott J, Coryell W, Paulus MP, Kunovac JL, Leon AC, Mueller TI, Rice JA, Keller MB: Major depressive disorder: a prospective study of residual subthreshold depressive symptoms as predictor of rapid relapse. J Affect Disord 1998, 50:97-108.
9. Judd LL, Paulus MJ, Schettler PJ, Akiskal HS, Endicott J, Leon AC, Maser JD, Mueller T, Solomon DA, Keller MB: Does incomplete recovery from first lifetime major depressive episode herald a chronic course of illness? Am J Psychiatry 2000, 157:1501-1504.
10. Judd LL, Akiskal HS, Maser JD, Zeller PJ, Endicott J, Coryell W, Paulus MP, Kunovac JL, Leon AC, Mueller TI, Rice JA, Keller MB: A pro-spective 12-year study of subsyndromal and syndromal depressive symptoms in unipolar major depressive disorders. Arch Gen Psychiatry 1998, 55:694-700.
11. Rush AJ, Trivedi MH: Treating depression to remission. Psychiatric Annals 1995, 25:704-705.
12. Thase ME: The clinical, psychosocial, and pharmacoeconomic ramifications of remission. Am J Manag Care 2001, 7:S377-S385.
13. Reesal RT, Lam RW: Clinical guidelines for the treatment of depressive disorders. II. Principles of management. Can J Psychiatry 2001, 46 Suppl 1:21S-28S.
14. Guy W: ECDEU Assessment Manual for Psychopharmacology: Publication ADM 76-338. Edited by: GuyW. Rockville, MD, US Department of Health, Education and Welfare; 1976:217-222.
15. Zimmerman M, Posternak MA, Chelminski I: Implications of using different cut-offs on symptom severity scales to define remission from depression. Int Clin Psychopharmacol 2004, 19:215-220.
16. Thase ME, Simons AD, McGeary J, Cahalane JF, Hughes C, Harden T, Friedman E: Relapse after cognitive behavior therapy of depression: potential implications for longer courses of treatment. Am J Psychiatry 1992, 149:1046-1052.
17. Fava GA, Fabbri S, Sonino N: Residual symptoms in depression: an emerging therapeutic target. Prog Neuropsychopharmacol Biol Psychiatry 2002, 26:1019-1027.
18. Miller IW, Keitner GI, Schatzberg AF, Klein DN, Thase ME, Rush AJ, Markowitz JC, Schlager DS, Kornstein SG, Davis SM, Harrison WM, Keller MB: The treatment of chronic depression, part 3: psychosocial functioning before and after treatment with sertraline or imipramine. J Clin Psychiatry 1998, 59:608-619.
19. American Psychiatric Association : Practice guideline for the treatment of patients with major depressive disorder (revision). Am J Psychiatry 2000, 157:1-45.
20. Bauer M, Whybrow PC, Angst J, Versiani M, Moller H-J, Disorders WFSBP Task Force on Treatment Guidelines for Unipolar Depressive: World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 1: Acute and continuation treatment of major depressive disorder. World Journal of Biological Psychiatry 2002, 3:5-43.
21. Depression Guideline Panel: Treatment of Major Depression. Clinical Practice Guideline. Washington, Agency for Health Care Policy and Research; 1993.
22. Thase ME, Entsuah AR, Rudolph RL: Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry 2001, 178:234-241.
23. Smith D, Dempster C, Glanville J, Freemantle N, Anderson I: Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a metaanalysis. Br J Psychiatry 2002, 180:396-404.
24. Casacalenda N, Perry JC, Looper K: Remission in major depressive disorder: a comparison of pharmacotherapy, psychotherapy, and control conditions. Am J Psychiatry 2002, 159:1354-1360.
25. Barrett JE, Barrett JA, Oxman TE, Gerber PD: The prevalence of psychiatric disorders in a primary care practice. Archives of General Psychiatry 1988, 45:1100-1106.
26. Katon W, Schulberg H: Epidemiology of depression in primary care. Gen Hosp Psychiatry 1992, 14:237-247.
27. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J: An inventory for measuring depression. Arch Gen Psychiatry 1961, 4:561-571.
28. Collaboration Cochrane: Cochrane Manual Oxford, Cochrane Collaboration; 2004.
29. Eddy DM, Hasselbald V, Shachter R: Meta-analysis by the confidence interval method. The statistical synthesis of evidence. San Diego, Academic Press Inc.; 1992.
30. Cuffel BJ, Azocar F, Tomlin M, Greenfield SF, Busch AB, Croghan TW: Remission, residual symptoms, and nonresponse in the usual treatment of major depression in managed clinical practice. J Clin Psychiatry 2003, 64:397-402.
31. Dowrick C, Dunn G, Ayuso-Mateos JL, Dalgard OS, Page H, Lehtinen V, Casey P, Wilkinson C, Vazquez-Barquero JL, Wilkinson G: Problem solving treatment and group psychoeducation for depression: multicentre randomised controlled trial. Outcomes of Depression International Network (ODIN) Group. British Medical Journal - Clinical Research 2000, 321:1450-1454.
32. Benkert O, Szegedi A, Kohnen R: Mirtazapine compared with paroxetine in major depression. J Clin Psychiatry 2000, 61:656-663.
33. Patris M, Bouchard JM, Bougerol T, Charbonnier JF, Chevalier JF, Clerc G, Cyran C, Van Amerongen P, Lemming O, Hopfner Petersen HE: Citalopram versus fluoxetine: a double-blind, controlled, multicentre, phase III trial in patients with unipolar major depression treated in general practice. Int Clin Psychopharmacol 1996, 11:129-136.
34. Wade A, Lemming O.Michael, Hedegaard K.Bang: Escitalopram 10 mg/day is effective and well tolerated in a placebo-controlled study in depression in primary care. International Clinical Psychopharmacology 2002, 17:95-102.
35. Chilvers C, Dewey M, Fielding K, Gretton V, Miller P, Palmer B, Weller D, Churchill R, Williams I, Bedi N, Duggan C, Lee A, Harrison G: Antidepressant drugs and generic counselling for treatment of major depression in primary care: randomised trial with patient preference arms. BMJ 2001, 322:772-775.
36. Mynors-Wallis LM, Gath DH, Lloyd-Thomas AR, Tomlinson D: Randomised controlled trial comparing problem solving treatment with amitriptyline and placebo for major depression in primary care. BMJ 1995, 310:441-445.
37. Mynors-Wallis LM, Gath DH, Day A, Baker F: Randomised controlled trial of problem solving treatment, antidepressant medication, and combined treatment for major depression in primary care. BMJ 2000, 320:26-30.
38. Schulberg HC, Pilkonis PA, Houck P: The severity of major depression and choice of treatment in primary care practice. J Consult Clin Psychol 1998, 66:932-938.
39. Scott AI, Freeman CP: Edinburgh primary care depression study: treatment outcome, patient satisfaction, and cost after 16 weeks. BMJ 1992, 304:883-887.
40. Katon W, Von Korff M., Lin E, Simon G, Walker E, Unutzer J, Bush T, Russo J, Ludman E: Stepped collaborative care for primary care patients with persistent symptoms of depression: a randomized trial. Arch Gen Psychiatry 1999, 56:1109-1115.
41. Katzelnick DJ, Simon GE, Pearson SD, Manning WG, Helstad CP, Henk HJ, Cole SM, Lin EH, Taylor LH, Kobak KA: Randomized trial of a depression management program in high utilizers of medical care. Arch Fam Med 2000, 9:345-351.
42. Kutcher S, Leblanc J, Maclaren C, Hadrava V: A randomized trial of a specific adherence enhancement program in sertralinetreated adults with major depressive disorder in a primary care setting. Prog Neuropsychopharmacol Biol Psychiatry 2002, 26:591-596.
43. Rost K, Nutting P, Smith JL, Elliott CE, Dickinson M: Managing depression as a chronic disease: a randomised trial of ongoing treatment in primary care. BMJ 2002, 325:934.